vx 497 has been researched along with Congenital Zika Syndrome in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bernatchez, JA; Li, J; Li, R; Luan, Y; Siqueira-Neto, JL; Tran, LT | 1 |
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Bukreyeva, N; Kalkeri, R; Koma, T; Kwong, AD; Manning, JT; Paessler, S; Smith, J; Tong, X | 1 |
1 review(s) available for vx 497 and Congenital Zika Syndrome
| Article | Year |
|---|---|
Drugs for the Treatment of Zika Virus Infection.
Topics: Animals; Antiviral Agents; Drug Development; Drug Discovery; Humans; Viral Vaccines; Zika Virus; Zika Virus Infection | 2020 |
2 other study(ies) available for vx 497 and Congenital Zika Syndrome
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Merimepodib, an IMPDH inhibitor, suppresses replication of Zika virus and other emerging viral pathogens.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line; Chlorocebus aethiops; Ebolavirus; Humans; IMP Dehydrogenase; Phenylurea Compounds; RNA, Viral; Vero Cells; Virus Replication; Zika Virus; Zika Virus Infection | 2018 |